This impact indicated their protective effects against the damage induced by MG treatment, although the mean area percentage of COX2 and caspase-3 +ve immunoreaction levels did not return ultimately to the baseline levels observed in the CONT group. This evidence concerns the gene PTGS2 and myasthenia gravis.